Racial Disparities in Intravenous Bisphosphonate Use Among Older Patients With Multiple Myeloma Enrolled in Medicare.
Jifang ZhouKaren I SweissEdith A NutescuJin HanPritesh R PatelNaomi Y KoTodd A LeeBrian C-H ChiuGregory Sampang CalipPublished in: JCO oncology practice (2021)
Approximately half of the patients with MM of age ≥ 65 years did not receive IV bisphosphonates, with significant delay among racial minority groups. These findings highlight the need for improvement of IV bisphosphonate uptake in patients with MM of age ≥ 65 years.